AMGN
Price
$307.16
Change
+$6.86 (+2.28%)
Updated
May 8, 2:56 PM EST
83 days until earnings call
BMY
Price
$44.01
Change
-$0.00 (-0.00%)
Updated
May 7, 6:59 PM EST
79 days until earnings call
Ad is loading...

AMGN vs BMY

Header iconAMGN vs BMY Comparison
Open Charts AMGN vs BMYBanner chart's image
Amgen
Price$307.16
Change+$6.86 (+2.28%)
Volume$13.48K
CapitalizationN/A
Bristol-Myers Squibb
Price$44.01
Change-$0.00 (-0.00%)
Volume$4.08M
CapitalizationN/A
View a ticker or compare two or three
AMGN vs BMY Comparison Chart

Loading...

AMGNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
BMYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AMGN vs. BMY commentary
May 09, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and BMY is a StrongSell.

COMPARISON
Comparison
May 09, 2024
Stock price -- (AMGN: $300.30 vs. BMY: $44.04)
Brand notoriety: AMGN and BMY are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 92% vs. BMY: 67%
Market capitalization -- AMGN: $151.69B vs. BMY: $109.66B
AMGN [@Pharmaceuticals: Major] is valued at $151.69B. BMY’s [@Pharmaceuticals: Major] market capitalization is $109.66B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 5 FA rating(s) are green whileBMY’s FA Score has 1 green FA rating(s).

  • AMGN’s FA Score: 5 green, 0 red.
  • BMY’s FA Score: 1 green, 4 red.
According to our system of comparison, AMGN is a better buy in the long-term than BMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 5 TA indicator(s) are bullish while BMY’s TA Score has 4 bullish TA indicator(s).

  • AMGN’s TA Score: 5 bullish, 5 bearish.
  • BMY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, AMGN is a better buy in the short-term than BMY.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а +9.62% price change this week, while BMY (@Pharmaceuticals: Major) price change was +0.23% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.11%. For the same industry, the average monthly price growth was -1.48%, and the average quarterly price growth was +3.36%.

Reported Earning Dates

AMGN is expected to report earnings on Jul 30, 2024.

BMY is expected to report earnings on Jul 26, 2024.

Industries' Descriptions

@Pharmaceuticals: Major (+1.11% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
A.I.dvisor published
a Summary for AMGN with price predictions.
OPEN
A.I.dvisor published
a Summary for BMY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
AMGN($152B) has a higher market cap than BMY($110B). AMGN has higher P/E ratio than BMY: AMGN (22.66) vs BMY (13.73). AMGN YTD gains are higher at: 5.075 vs. BMY (-13.173). BMY has higher annual earnings (EBITDA): 19.4B vs. AMGN (14.8B). BMY has more cash in the bank: 12.3B vs. AMGN (10.9B). BMY has less debt than AMGN: BMY (41.5B) vs AMGN (64.6B). BMY has higher revenues than AMGN: BMY (45B) vs AMGN (28.2B).
AMGNBMYAMGN / BMY
Capitalization152B110B138%
EBITDA14.8B19.4B76%
Gain YTD5.075-13.173-39%
P/E Ratio22.6613.73165%
Revenue28.2B45B63%
Total Cash10.9B12.3B89%
Total Debt64.6B41.5B156%
FUNDAMENTALS RATINGS
AMGN vs BMY: Fundamental Ratings
AMGN
BMY
OUTLOOK RATING
1..100
2055
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
25
Undervalued
PROFIT vs RISK RATING
1..100
1282
SMR RATING
1..100
1239
PRICE GROWTH RATING
1..100
2164
P/E GROWTH RATING
1..100
790
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMGN's Valuation (16) in the Biotechnology industry is in the same range as BMY (25) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to BMY’s over the last 12 months.

AMGN's Profit vs Risk Rating (12) in the Biotechnology industry is significantly better than the same rating for BMY (82) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than BMY’s over the last 12 months.

AMGN's SMR Rating (12) in the Biotechnology industry is in the same range as BMY (39) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to BMY’s over the last 12 months.

AMGN's Price Growth Rating (21) in the Biotechnology industry is somewhat better than the same rating for BMY (64) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than BMY’s over the last 12 months.

AMGN's P/E Growth Rating (7) in the Biotechnology industry is significantly better than the same rating for BMY (90) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than BMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNBMY
RSI
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
44%
Momentum
ODDS (%)
Bullish Trend 2 days ago
59%
Bearish Trend 2 days ago
52%
MACD
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 6 days ago
43%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
56%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
55%
Bearish Trend 2 days ago
52%
Advances
ODDS (%)
Bullish Trend 6 days ago
59%
Bullish Trend 17 days ago
57%
Declines
ODDS (%)
Bearish Trend 14 days ago
53%
Bearish Trend 9 days ago
54%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
57%
Bullish Trend 2 days ago
59%
Aroon
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
47%
View a ticker or compare two or three
Ad is loading...
AMGNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
BMYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CNTA9.670.42
+4.54%
Centessa Pharmaceuticals plc
RUSHA45.020.82
+1.86%
Rush Enterprises
AOMR11.36-0.05
-0.44%
Angel Oak Mortgage REIT
DAL52.20-0.73
-1.38%
Delta Air Lines
CUTR2.75-0.11
-3.85%
Cutera

AMGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with GILD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then GILD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGN
1D Price
Change %
AMGN100%
+0.27%
GILD - AMGN
46%
Loosely correlated
-0.12%
JNJ - AMGN
35%
Loosely correlated
+0.09%
BIIB - AMGN
33%
Loosely correlated
-1.13%
ABBV - AMGN
33%
Poorly correlated
-0.11%
MRK - AMGN
30%
Poorly correlated
+2.20%
More

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
+0.32%
PFE - BMY
41%
Loosely correlated
-1.38%
JNJ - BMY
40%
Loosely correlated
+0.09%
BIIB - BMY
34%
Loosely correlated
-1.13%
GILD - BMY
33%
Loosely correlated
-0.12%
AMGN - BMY
32%
Poorly correlated
+0.27%
More